Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
3.770
-0.190 (-4.80%)
At close: Jan 15, 2026, 4:00 PM EST
3.790
+0.020 (0.53%)
After-hours: Jan 15, 2026, 6:59 PM EST
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $180 million as of January 15, 2026. Its market cap has increased by 44.73% in one year.
Market Cap
180.00M
Enterprise Value
4.75M
1-Year Change
44.73%
Ranking
Category
Stock Price
$3.77
Market Cap Chart
Since August 10, 2021, Climb Bio's market cap has decreased from $403.20M to $180.00M, a decrease of -55.36%. That is a compound annual growth rate of -16.62%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 15, 2026 | 180.00M | -5.75% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
| Aug 10, 2021 | 403.20M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 964.49B |
| Johnson & Johnson | 514.75B |
| AbbVie | 390.15B |
| UnitedHealth Group | 302.49B |
| AstraZeneca | 291.77B |
| Novartis AG | 272.12B |
| Merck & Co. | 268.70B |
| Novo Nordisk | 265.30B |